Table 2. Promoter transcription factor-binding motif distributions for candidate transcription control pathways.

	MDD versus Control		MDD baseline versus antidepressant Tx
	Observed	Adjusteda	Observed	Adjusteda
CREB	2.66±0.20, P=0.0007b	2.40±0.17, P=0.0005b	1.04±0.10, P=0.6872	2.63±0.12, P=0.0001b
ISRE	1.46±0.39, P=0.3091	0.64±0.17, P=0.0482	3.14±0.20, P=0.0003b	4.17±0.36, P=0.0098
NRF2	2.11±0.18, P=0.0019b	1.72±0.09, P=0.0003b	0.61±0.08, P=0.0002b	0.48±0.14, P=0.0005b
NF-κB	0.92±0.03, P=0.0480	0.96±0.04, P=0.3067	1.43±0.12, P=0.0115	0.81±0.06, P=0.0078
GR	1.05±0.06, P=0.4198	1.01±0.06, P=0.9164	0.91±0.10, P=0.3437	0.82±0.14, P=0.1747
EGR1	1.10±0.10, P=0.4216	1.34±0.09, P=0.0230	0.83±0.08, P=0.0685	2.59±0.21, P=0.0042b
EGR2	0.42±0.23, P=0.0140	0.70±0.08, P=0.0017b	0.82±0.09, P=0.0483	1.67±0.13, P=0.0025b
EGR3	0.41±0.43, P=0.0665	0.58±0.65, P=0.0016b	0.69±0.13, P=0.0139	2.86±0.12, P=0.0001b
EGR4/NGFIC	0.53±0.36, P=0.1113	0.82±0.16, P=0.2233	0.89±0.09, P=0.2128	2.47±0.25, P=0.0101

Abbreviations: CREB, cAMP response element-binding; EGR, early growth response; GR, glucocorticoid receptor; ISRE, interferon-stimulated response element; MDD, major depressive disorder; NF-κB, nuclear factor kappa-B; NRF2, nuclear factor erythroid-derived 2-like 2; PBMC, peripheral blood mononuclear cell; TFBM, transcription factor-binding motif.

Values represent the mean fold difference in promoter TFBM distribution±s.e., and two-tailed P-value testing null hypothesis 1.0-fold

.

^aAnalyses controlling for age, sex and PBMC % lymphocytes, monocytes and eosinophils.

^bStatistically significant under Bonferroni correction for simultaneous testing of nine pathways (individual P<0.0056).